Subscribe to NRx Newsletter

Home

Hope • Science • Life

6th Annual Sachs Associates Neuroscience Innovation Forum

NRx Pharmaceuticals presented a corporate and scientific update at the Neurology Innovation Forum, held on January 8, 2023, in San Francisco, California.

6th Annual Sachs Associates Neuroscience Innovation Forum

NRx Pharmaceuticals presented a corporate and scientific update at the Neurology Innovation Forum, held on January 8, 2023, in San Francisco, California.

We bring
hope to life

People facing life-threatening diseases need the possibility of tomorrow. We bring them hope through life-saving medicines.

We bring
hope to life

People facing life-threatening diseases need the possibility of tomorrow. We bring them hope through life-saving medicines.

Discover Our Pipeline

We go after the most critical medical conditions and unmet needs.

Discover Our Pipeline

We go after the most critical medical conditions and unmet needs.

Resources & Patient Stories

We aim to develop innovative, life-saving treatments and thereby bring hope to those facing life-altering conditions with no approved therapies.

Click here for Bipolar Depression Trial (NRX-101)

Resources & Patient Stories

We aim to develop innovative, life-saving treatments and thereby bring hope to those facing life-altering conditions with no approved therapies.

Click here for Bipolar Depression Trial (NRX-101)

NRX-101

NRX-101 – our drug in development for Bipolar Depression in patients with Acute and Subacute Suicidal Ideation & Behavior

Learn more about our clinical trial for severe bipolar depression with Sub-Acute Suicidal Ideation & Behavior (SSIB).

Latest news

Highlights

As many as 50% of individuals with bipolar disorder attempt suicide or have serious thoughts of suicide and between 11-20% of those attempt and succumb to suicide.





Source:
Pallaskorpi, et al. “Incidence and predictors of suicide attempts in bipolar I and II disorders: A 5-year follow-up study,” Bipolar Disorders, 2016
“Suicide Attempts and Completions in Patients With Bipolar Disorder,” Psychiatric Times, 2007

NRX-101 is an investigational treatment for bipolar depression in patients with Acute and Sub-Acute Suicidal Ideation and Behavior (ASIB, SSIB)

Today, no medicine is approved to specifically treat bipolar depression in patients with high levels of suicidal ideation.

NRX-101 is a patented, oral fixed-dose combination of two FDA-approved drugs: D-cycloserine, an NMDA receptor modulator; and Lurasidone, a 5-HT2a receptor antagonist.

Discovery Pipeline

We are advancing the development of the first oral investigational medicine to treat Bipolar Depression in Patients with ASIB and SSIB.

We are also exploring opportunities in other CNS disease areas such as Post-Traumatic Stress Disorder (PTSD).

Each product in our pipeline has potential for additional indications beyond their initial target indications, and with this, we can save more lives and hope may become reality for even more people.

What Makes Us Different?

We apply innovative science to known molecules.

We focus our efforts to address critical medical conditions that are not being pursued others, such as severe bipolar depression with Acute suicidality.

We work to research and develop medicines for people that desperately need them. We accomplish our mission by directing scientific and clinical expertise towards innovative clinical protocols.

Stories

Appreciating the value of a breath

One of the tragic results of the pandemic years is the deteriorating mental health of many Americans — a vicious trend that has spared no one.